Objective:
Cytomegalovirus infection is the most frequent congenital infection and a major cause of long-term neurologic morbidity. The aim of this meta-analysis was to calculate the pooled rates of vertical transmission and fetal impairments according to the timing of primary maternal infection.
Data Sources:
From inception to January 2020, MEDLINE, Scopus, Cochrane Library, and gray literature sources were used to search for related studies.
Study Eligibility Criteria:
Cohort and observational studies reporting the timing of maternal cytomegalovirus infections and rate of vertical transmission or fetal impairments were included. The primary outcomes were vertical transmission and fetal insult, defined as either prenatal findings from the central nervous system leading to termination of pregnancy or the presence of neurologic symptoms at birth. The secondary outcomes included sensorineural hearing loss or neurodevelopmental delay at follow-up and prenatal central nervous system ultrasonography findings.
Study Appraisal And Synthesis Methods:
The pooled rates of the outcomes of interest with their 95% confidence intervals (CI) were calculated for primary maternal infection at the preconception period, periconception period, first trimester, second trimester, and third trimester.
Results:
A total of 17 studies were included. The pooled rates of vertical transmission (10 studies, 2942 fetuses) at the preconception period, periconception period, first trimester, second trimester, and third trimester were 5.5% (95% CI, 0.1-10.8), 21.0% (95% CI, 8.4-33.6), 36.8% (95% CI, 31.9-41.6), 40.3% (95% CI, 35.5-45.1), and 66.2% (95% CI, 58.2-74.1), respectively. The pooled rates of fetal insult in case of transmission (10 studies, 796 fetuses) were 28.8% (95% CI, 2.4-55.1), 19.3% (95% CI, 12.2-26.4), 0.9% (95% CI, 0-2.4%), and 0.4% (95% CI, 0-1.5), for maternal infection at the periconception period, first trimester, second trimester, and third trimester, respectively. The pooled rates of sensorineural hearing loss for maternal infection at the first, second, and third trimester were 22.8% (95% CI, 15.4-30.2), 0.1% (95% CI, 0-0.8), and 0% (95% CI, 0-0.1), respectively.
Conclusion:
Vertical transmission after maternal primary cytomegalovirus infection increases with advancing pregnancy, starting from the preconception period. However, severe fetal impairments are rare after infection in the first trimester of pregnancy.
Citing Articles
The Angiogenic Markers PlGF and sFlt-1 in Cytomegalovirus Infection During Pregnancy: Insights from a Clinical Case.
Giardini V, Chiozzi R, Fernicola F, Casati M, Locatelli A, Ornaghi S
Viruses. 2025; 17(2).
PMID: 40007022
PMC: 11860600.
DOI: 10.3390/v17020267.
Proceedings of the Conference "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).
Schleiss M, Crooks C, Karthigeyan K, Kruc R, Otero C, Wang H
Vaccines (Basel). 2024; 12(11).
PMID: 39591134
PMC: 11598149.
DOI: 10.3390/vaccines12111231.
Progress and Challenges in the Management of Congenital Cytomegalovirus Infection.
Szulc W, Szydlowska N, Smyk J, Majewska A
Clin Pract. 2024; 14(6):2445-2462.
PMID: 39585019
PMC: 11587044.
DOI: 10.3390/clinpract14060191.
Audiological and Vestibular Follow-Up for Children with Congenital Cytomegalovirus Infection: From Current Limitations to Future Directions.
Alde M, Fancello V, Di Mauro P, Canelli R, Zaouche S, Falanga C
Children (Basel). 2024; 11(10).
PMID: 39457176
PMC: 11506510.
DOI: 10.3390/children11101211.
Cytomegalovirus and pregnancy: current evidence for clinical practice.
Pontes K, Araujo Junior E
Rev Assoc Med Bras (1992). 2024; 70(8):e20240509.
PMID: 39230148
PMC: 11370743.
DOI: 10.1590/1806-9282.20240509.
Discrimination of primary and chronic cytomegalovirus infection based on humoral immune profiles in pregnancy.
Hederman A, Remmel C, Sharma S, Natarajan H, Weiner J, Wrapp D
J Clin Invest. 2024; 134(20).
PMID: 39207860
PMC: 11473158.
DOI: 10.1172/JCI180560.
Cytomegalovirus-Specific Hyperimmune Immunoglobulin Administration for Secondary Prevention after First-Trimester Maternal Primary Infection: A 13-Year Single-Center Cohort Study.
Karofylakis E, Thomas K, Kavatha D, Galani L, Tsiodras S, Giamarellou H
Viruses. 2024; 16(8).
PMID: 39205215
PMC: 11359551.
DOI: 10.3390/v16081241.
Immune surveillance of cytomegalovirus in tissues.
Mihalic A, Zeleznjak J, Lisnic B, Jonjic S, Juranic Lisnic V, Brizic I
Cell Mol Immunol. 2024; 21(9):959-981.
PMID: 39134803
PMC: 11364667.
DOI: 10.1038/s41423-024-01186-2.
What are the neurodevelopmental outcomes of children with asymptomatic congenital cytomegalovirus infection at birth? A systematic literature review.
Smyrli A, Raveendran V, Walter S, Pagarkar W, Field N, Kadambari S
Rev Med Virol. 2024; 34(4):e2555.
PMID: 39031854
PMC: 11262424.
DOI: 10.1002/rmv.2555.
Establishing Correlates of Maternal-Fetal Cytomegalovirus Transmission-One Step Closer Through Predictive Modeling.
Marchant A, Adali S, Alsdurf H, Bol V, Capelle X, De Schrevel N
J Infect Dis. 2024; 230(6):e1274-e1286.
PMID: 38865084
PMC: 11646613.
DOI: 10.1093/infdis/jiae281.
Characterization of Natural Killer Cell Profile in a Cohort of Infected Pregnant Women and Their Babies and Its Relation to CMV Transmission.
Pighi C, Rotili A, De Luca M, Chiurchiu S, Calo Carducci F, Rossetti C
Viruses. 2024; 16(5).
PMID: 38793661
PMC: 11125694.
DOI: 10.3390/v16050780.
Is a Higher Amniotic Fluid Viral Load Associated with a Greater Risk of Fetal Injury in Congenital Cytomegalovirus Infection-A Systematic Review and Meta-Analysis.
Gilad N, Agrawal S, Philippopoulos E, Murphy K, Shinar S
J Clin Med. 2024; 13(7).
PMID: 38610901
PMC: 11012373.
DOI: 10.3390/jcm13072136.
Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI).
Leruez-Ville M, Chatzakis C, Lilleri D, Blazquez-Gamero D, Alarcon A, Bourgon N
Lancet Reg Health Eur. 2024; 40:100892.
PMID: 38590940
PMC: 10999471.
DOI: 10.1016/j.lanepe.2024.100892.
Performance of eight commercial immunoassays for the detection of cytomegalovirus-specific IgM antibodies in pregnancy - no test fits all needs.
Daiminger A, Beck R, Exler S, Bartelt U, Enders M
J Clin Microbiol. 2024; 62(4):e0140723.
PMID: 38426762
PMC: 11005438.
DOI: 10.1128/jcm.01407-23.
Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis.
Leber A
J Clin Microbiol. 2024; 62(4):e0031323.
PMID: 38391188
PMC: 11005381.
DOI: 10.1128/jcm.00313-23.
Early detection of active Human CytomegaloVirus (hCMV) infection in pregnant women using data generated for noninvasive fetal aneuploidy testing.
Faas B, Astuti G, Melchers W, Reuss A, Gilissen C, Macville M
EBioMedicine. 2024; 100:104983.
PMID: 38365322
PMC: 10878988.
DOI: 10.1016/j.ebiom.2024.104983.
Cytomegalovirus and Pregnancy: A Narrative Review.
Pontes K, Nardozza L, Peixoto A, Werner H, Tonni G, Granese R
J Clin Med. 2024; 13(2).
PMID: 38276146
PMC: 10816506.
DOI: 10.3390/jcm13020640.
Anti-CMV therapy, what next? A systematic review.
Gourin C, Alain S, Hantz S
Front Microbiol. 2023; 14:1321116.
PMID: 38053548
PMC: 10694278.
DOI: 10.3389/fmicb.2023.1321116.
Congenital cytomegalovirus infection: the state of the art and future perspectives.
Salome S, Corrado F, Mazzarelli L, Maruotti G, Capasso L, Blazquez-Gamero D
Front Pediatr. 2023; 11:1276912.
PMID: 38034830
PMC: 10687293.
DOI: 10.3389/fped.2023.1276912.
Knowledge and attitudes of medical students about clinical aspects of congenital cytomegalovirus infection in newborns: A nationwide cross-sectional study in Greece.
Benou S, Hatzidaki E, Kalaintzi A, Grivea I, Baltogianni M, Giapros V
Front Med (Lausanne). 2023; 10:1256704.
PMID: 38034533
PMC: 10687632.
DOI: 10.3389/fmed.2023.1256704.